Table 1.
Substrate specificities of BlAga3.
| Substrate | Structure | Conc. (mM) |
Specific activity (unit/mg) |
Relative activityg (%) |
|---|---|---|---|---|
| GAa | αGal-(1→3)-L-Ara* | 2.0 | 101 | 100 |
| pNP-α-Gala | αGal-pNP | 5.0 | 337 | 335 |
| Melibioseb | αGal-(1→6)-Glc* | 5.0 | 23.6 | 23.4 |
| Raffinoseb | αGal-(1→6)-αGlc-(1↔2)-βFruf | 5.0 | 48.0 | 47.7 |
| Stachyoseb | αGal-(1→6)-αGal-(1→6)-αGlc-(1↔2)-βFruf | 5.0 | 3.38 | 3.36 |
| GA-Meb | αGal-(1→3)-α-L-Araf-OMe | 2.0 | 22.4 | 22.3 |
| AAc, f | β-L-Arap-(1→3)-L-Ara* | 2.0 | 0.647 | 0.643 |
| AA-Mec | β-L-Arap-(1→3)-α-L-Araf-OMe | 2.0 | Trace | Trace |
| pNP-β-Arapc | β-L-Arap-pNP | 5.0 | 1.06 | 1.06 |
| Liner B-2 trisaccharided | αGal-(1→3)-βGal-(1→4)-GlcNAc* | 0.5 | 17.2 | 17.1 |
| Blood group B trisaccharidee | αGal-(1→3)-[αFuc-(1→2)]-Gal* | 0.5 | 0.610 | 0.607 |
| Blood group B pentasaccharidee | αGal-(1→3)- [αFuc-(1→2)]-βGal-(1→4)- [αFuc-(1→3)]-Glc* | 0.05 | Trace | Trace |
| S3GAe | αGal-(1→3)-α-L-Araf-(1→3)- [α-L-Araf-(1→4)]-βGal-(1→6)-Gal* | 0.5 | 0.643 | 0.639 |
| S5GAe | αGal-(1→3)-α-L-Araf-(1→3)-[αRha-(1→4)-βGlcA-(1→6)]-[α-L-Araf-(1→4)]-βGal-(1→6)-Gal* | 0.5 | 0.514 | 0.511 |
*Represents reducing end of the oligosaccharide. a 0.099 μg/mL BlAga3 was incubated for 20 min. b 0.099 μg/mL BlAga3 was incubated for 2 h. c 0.099 μg/mL BlAga3 was incubated for 6 h. d 0.020 μg/mL BlAga3 was incubated for 1 h. e 0.020 μg/mL BlAga3 was incubated for 5 h. f The specific activity was calculated on the value for released L-arabinose by one-half. g Relative activity is expressed as the percentage of the activity toward α-D-Gal-(1→3)-L-Ara.